ATS Medical Inc.


in
ATS Medical Inc. announced the first North American commercial implant of the ATS 3f(R) Aortic Bioprosthesis. Canadian regulatory approval was received at the end of December, 2007. The ATS 3f Aortic Bioprosthesis incorporates revolutionary design concepts intended to preserve native aortic root geometry and function. Through this unique approach, the prosthesis more closely mimics native valve function providing excellent hemodynamic performance that may contribute to improvements in key determinants of cardiovascular performance such as coronary blood flow and left ventricular mass regression. Data suggests that physiologic stresses, a detriment to bioprosthetic valve longevity, may be more efficiently distributed throughout the prosthetic's leaflets.